Grants & Programs

Immunology & Immunotherapy: From Discovery to Development to Drug

September 14, 2008
09:00 AM
Millennium Conference Center, New York, NY

Scientists from academia and industry joined together to present and discuss data from the latest laboratory investigations as well as both early- and late-phase clinical trials of cancer immunotherapies at “Cancer Immunology & Immunotherapy 2008: From Discovery to Development to Drug,” held September 15-17, 2008, at the Millennium Conference Center in New York City. The 16th Annual International Cancer Immunotherapy Symposium, combined with the 2008 Colloquium of the Cancer Immunotherapy Consortium, attracted 350 immunologists and tumor immunologists from 165 academic institutions and biotech or pharmaceutical companies in 17 countries. The meeting featured 27 plenary lectures and a poster session presenting the research of 100 scientists working within immunology and tumor immunology.

Download Final Program (PDF)

Cancer Immunoediting and Cancer and Inflammation

  • Adrian Hayday, Kings College School of Medicine at Guy's Hospital
  • Glenn Dranoff, Dana-Farber Cancer Institute
  • Wolf H. Fridman, INSERM, University Paris Descartes and University Pierre et Marie Curie
  • Robert D. Schreiber, Washington University School of Medicine
  • Mark J. Smyth, Peter MacCallum Cancer Centre

Immunological Consequences of Current Cancer Therapy

  • Hyam Levitsky, John Hopkins University School of Medicine
  • Jeffrey V. Ravetch, The Rockefeller University
  • Padmanee Sharma, The University of Texas M.D. Anderson Cancer Center
  • Laurence Zitvogel, Institut Gustave Roussy

Cross Presentation and Tumor Stroma

  • Michael J. Bevan, University of Washington School of Medicine
  • George Coukos, University of Pennsylvania Medical Center
  • Gunter J. Hämmerling, German Cancer Research Center, DKFZ Heidelberg
  • Ellen Puré, The Wistar Institute
  • Pramod K. Srivastava, Center for Immunotherapy of Cancer and Infectious Diseases

Modulators of Immune Escape Mechanisms

  • James P. Allison, Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center
  • Vincenzo Bronte, Istituto Oncologico Veneto and Venetian Institute for Molecular Medicine
  • Arlene H. Sharpe, Harvard Medical School and Brigham and Women's Hospital
  • Michail V. Sitkovsky, N.E. Infl ammation and Tissue Protection Institute, Northeastern University

Adoptive Immunotherapy

  • Carl June, Abramson Cancer Center, University of Pennsylvania
  • Michel Sadelain, Memorial Sloan-Kettering Cancer Center
  • Cassian Yee, Fred Hutchinson Cancer Research Center and University of Washington

Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials

  • David Berman, Bristol-Myers Squibb
  • Sacha Gnjatic, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center
  • Cecile Gouttefangeas, University of Tübingen
  • Kristen Hege, Cell Genesys, Inc.
  • Frederic Lehmann, GlaxoSmithKline Biologicals
  • Jedd Wolchok, Memorial Sloan-Kettering Cancer Center